Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.

Prevrhal S, Krege JH, Chen P, Genant H, Black DM

Current medical research and opinion1 Apr 2009Cited by 40 (Europe PMC)

PMID19250060DOI10.1185/03007990902790993PepBankPUB-19250060

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In the Fracture Prevention Trial, teriparatide reduced vertebral fracture risk versus placebo using combined quantitative and semiquantitative assessment.
In plain wordsIn the fracture trial, teriparatide reduced spine fracture risk versus placebo using combined X-ray assessments.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIncident vertebral fracture
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Measurements
Risk reduction
84%
teriparatide versus placebo
RR
0.16 ratio
teriparatide versus placebo
Source sentences
Summary
By this methodology, vertebral fracture risk was reduced in the teriparatide versus placebo group by 84% (RR = 0.16, p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs from the Fracture Prevention Trial placebo- and teriparatide 20 microg/day groups were re-assessed in blinded fashion,
Report a problemFND-1925006001
02HumanNon-randomized trialEfficacy outcome
In the Fracture Prevention Trial, teriparatide reduced the risk of multiple vertebral fractures versus placebo.
In plain wordsIn the fracture trial, teriparatide reduced the risk of multiple spine fractures versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTwo or more vertebral fractures
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Measurements
Risk reduction
94%
teriparatide versus placebo
RR
0.06 ratio
teriparatide versus placebo
Source sentences
Summary
The risk of two or more vertebral fractures was also significantly reduced by 94% (RR = 0.06, p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs from the Fracture Prevention Trial placebo- and teriparatide 20 microg/day groups were re-assessed in blinded fashion,
Report a problemFND-1925006002
03HumanNon-randomized trialEfficacy outcome
In the Fracture Prevention Trial, vertebral fractures were less severe with teriparatide than placebo.
In plain wordsIn the fracture trial, spine fractures were less severe with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral fracture severity
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/dayAs given in this study (human).
Source sentences
Summary
The fractures in the teriparatide group were of lesser severity than the fractures in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs from the Fracture Prevention Trial placebo- and teriparatide 20 microg/day groups were re-assessed in blinded fashion,
Report a problemFND-1925006003

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In the fracture trial, teriparatide's absolute benefit was greatest in patients with the highest number and severity of prevalent vertebral fractures.
In plain wordsIn the fracture trial, teriparatide's absolute benefit was greatest with the highest number and severity of existing spine fractures.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAbsolute benefit by prevalent fracture burden
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The absolute benefit of teriparatide was greatest in those patients with the highest number and severity of prevalent vertebral fractures.
1 context sentence(design, population, supporting numbers)
Summary · context
Radiographs from the Fracture Prevention Trial placebo- and teriparatide 20 microg/day groups were re-assessed in blinded fashion,
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1925006004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00670501

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Eli Lilly and Companyn = 1,637Aug 1996 to Apr 1999

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 1 May 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.